Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide

<table>Clinical course of Case <a href="https://static.hindawi.com/articles/crihem/volume-2013/651902/figures/#casee2">2</a>. BD: bortezomib plus dexamethasone; CY: cyclophosphamide; Hb: hemoglobin; PLT: platelet counts; WBC: white blood cell counts; and neut.: neutrophil count.</table>

Case Reports in Hematology

fig2

Figure 2

Figure 2: Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide 

Figure 2 | Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide 